MacroGenics Inc (MGNX)

NASDAQ
3.98
+0.08(+2.05%)
After Hours
4.12
+0.14(+3.52%)
- Real-time Data
  • Volume:
    815,540
  • Day's Range:
    3.79 - 4.14
  • 52 wk Range:
    3.76 - 32.81

MGNX Overview

Prev. Close
3.9
Day's Range
3.79-4.14
Revenue
71.67M
Open
3.99
52 wk Range
3.76-32.81
EPS
-3.56
Volume
815,540
Market Cap
244.11M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
757,886
P/E Ratio
-
Beta
2.26
1-Year Change
-86.8%
Shares Outstanding
61,333,500
Next Earnings Date
Aug 03, 2022
What is your sentiment on MacroGenics Inc?
or
Market is currently closed. Voting is open during market hours.

MacroGenics Inc News

  • Macrogenics Misses Q1 EPS by 22c
    • ByInvesting.com-

    Macrogenics (MGNX) reported Q1 EPS of ($1.08), $0.22 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $11.1 million versus the consensus estimate of...

  • Barclays Stick to Their Buy Rating for MacroGenics
    • ByInvesting.com-

    Barclays (LON:BARC) analyst Peter Lawson maintained a Buy rating on MacroGenics (NASDAQ:MGNX) on Wednesday, setting a price target of $35, which is approximately 61.51% above the...

MacroGenics Inc Analysis

MacroGenics Inc Company Profile

MacroGenics Inc Company Profile

Employees
427

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell
  • Fda approved mgnx for breast cancer treatment today, deff buying it tom !!
    0
    • You can buy it now why wait till tomorrow ?
      0
  • why a drastic fall ?
    0
    • why is this still in its 20s?
      0
      • any news on MGNX ? why such as drastic crash ?
        0
        • No FDA approval it's going to drop like rock!
          0
          • so buy or dont ?
            2
            • this company is pretty good the more I look at them.  could be a good buy out from a larger company.  If it gets sold this thing will sky rocket.  Shorting for now but will keep an eye on it after I cover
              0
              • added to watch list - but will crashhhhh on Friday
                0
                • interesting stock...getting a bump in AH trading..still shorting the ******out of it though
                  0
                  • Stair stepping Down........Watch out for that last step!!! Holy Moly 🙀
                    0